Compare Amylx Pharmaceuticals Inc (AMLX) vs Etsy Inc (ETSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Etsy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Etsy Inc trades at $80.74 (market cap $7.69B). The key difference: Etsy Inc is far larger — about 3.9× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMLX | ETSY | |
|---|---|---|
Market Cap | $1.98B | $7.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $81.05 |
52-Week Low | $7.64 | $44.05 |
Enterprise Value | $1.70B | $9.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
ETSY trades at $81.05, up 4.28% recently, with a bullish technical outlook supported by positive moving averages and recent earnings beats. The company shows strong gross margins of 71.55% and positive cash flow trends, though net income declined to $162.98M in 2025. Analyst sentiment is mixed with 49% buy ratings but a consensus price target of $70.79 below current levels, highlighting valuation concerns amid competitive pressures.
Outlook remains cautious due to high P/E of 31.05 and negative shareholder equity, offset by operational improvements and AI-driven seller tools. Key risks include active buyer declines and heavy debt load, but sustained GMS growth and cost management could support recovery if execution strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
